Indaptus Therapeutics Announces New Data From Ongoing Phase 1 Trial Of Decoy20; Latest Data From First And Second Cohorts Support Company's 'Pulse-Prime' Approach, Demonstrating Rapid Clearance, Broad Immune Activation, And Encouraging Safety Profile
Indaptus Therapeutics Announces New Data From Ongoing Phase 1 Trial Of Decoy20; Latest Data From First And Second Cohorts Support Company's 'Pulse-Prime' Approach, Demonstrating Rapid Clearance, Broad Immune Activation, And Encouraging Safety Profile
Latest data from first and second cohorts support Company's 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile
第一和第二批次的最新數據支持公司的“pulse-prime”方法，展示了快速清除、廣泛免疫激活和鼓舞人心的安全概況。
Poster Presented at American Society of Clinical Oncology Annual Meeting
在美國臨床腫瘤學會年會上展示了海報。
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced updated data from its ongoing Phase 1 clinical trial of Decoy20 in patients with solid tumors. The data were featured in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1 in Chicago, Illinois.
納斯達克(NASDAQ：INDP)生物技術公司Indaptus Therapeutics Inc致力於開發創新的癌症和病毒感染治療方法的臨床階段生物技術公司，今天宣佈了Decoy20正在進行的一項治療實體瘤患者的I期臨床試驗的更新數據。這些數據被特色板塊於2024年6月1日在伊利諾伊州芝加哥市美國臨床腫瘤學會(ASCO)年會的一份海報展示。
譯文內容由第三人軟體翻譯。